Overview
Germany dialysis provider's Q1 revenue met analyst expectations, organic growth offset by currency effects
Adjusted EPS for Q1 rose 8% yr/yr, supported by share buybacks
Company completed EUR 1.0 bln share buyback, repurchasing 24.8 mln shares
Outlook
Fresenius Medical Care expects 2026 revenue growth to be broadly flat versus prior year
Company sees 2026 operating income growth between negative and positive mid-single digit percent
2025 baseline for outlook is EUR 19,628 mln revenue and EUR 2,212 mln operating income
Result Drivers
CURRENCY EFFECTS - Significant negative currency movements weighed on reported revenue and operating income
TRANSFORMATION COSTS - One-time costs from the FME25+ transformation program, including clinic closures, drove the decline in reported operating income and net income
TDAPA AND PAYOR MIX - Positive impact from U.S. TDAPA reimbursement regulations and favorable rate and payor mix supported operating income, per CEO Helen Giza
Company press release: ID:nPn1nkJpHa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Meet
EUR 4.61 bln
EUR 4.61 bln (7 Analysts)
Q1 Net Income
EUR 118 mln
Q1 Basic EPS
EUR 0.43
Q1 EBIT
EUR 286 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and 7 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fresenius Medical Care AG is €43.00, about 10.6% above its May 4 closing price of €38.87
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)